(220) Amphotericin B Nanocrystals-in-Nanofibers Films for the Topical Treatment of Cutaneous Leishmaniasis

Introduction: Cutaneous leishmaniasis (CL) is a neglected vector-borne skin disease that affects up to 1,000,000 individuals annually across 90 endemic countries, mainly impacting children and impoverished communities [1]. Current treatments are limited by high costs, toxicity, poor efficacy, and challenging administration protocols [2]. This work aims to produce a topical treatment consisting of amphotericin B (AmB) nanocrystals (NCs) delivered via nanofiber (NF) wound healing films, providing a minimally invasive, self-administered, and cost-effective solution to this urgent global health challenge.